CTXRNasdaqPharmaceutical PreparationsFiscal year ends September 30
Citius Pharmaceuticals, Inc.
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.43−0.03 (-7.00%)
Close on Oct 19, 2026
- Market cap
- $11.20M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$1.0222 (−70.50%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $11.20M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.17
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- EPS, diluted
- -$2.13
- Book value per share
- $2.55
- Diluted shares
- 26M
Twelve years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
–
Gross profit
–
Operating income
-$61.38M
Net income
–
EPS, diluted
-$2.13
Free cash flow
–
Reported periodTrailing twelve months